Since the start of the COVID pandemic, there has been more attention given to problems of mental ill-health including depression than ever before. A new therapeutic option, especially for depression, ...

NeuroStar-related presentations at CTMSS reflect the Company’s commitment to advancing TMS research and learning from real-world evidence. The Company continues to explore treatment outcomes across ...

Device-based neuromodulation therapies may offer a viable alternative for patients with depression who do not achieve adequate response to SSRIs.

Transcranial magnetic stimulation (TMS) was approved by the FDA to treat some patients with depression in 2008, and has since been used in treatment plans for a variety of other health issues. But the ...

Not only is depression a debilitating disease, but it is also widespread. Approximately 20 million adult Americans experience at least one episode of depression per year. One promising treatment for ...

The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine was among the most celebrated breakthroughs of the ongoing pandemic. Along with the Moderna vaccine ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Neuronetics’ NeuroStar Advanced Therapy for Mental Health, a transcranial magnetic ...